CRSP EBITDA Growth
Crispr Therapeutics Ag · EBITDA Growth
CRSP EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-2.06%period ending
CRSP TTM EBITDA YoY % (-158.50% → -2.06%)
Year-over-year change
High-resolution chart · PNG
CRSP ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -2.0593% | |
| -50.6409% | |
| -62.6314% | |
| -114.5531% | |
| -82.5833% | |
| -85.695% | |
| -162.3723% | |
| 36.0494% | |
| 39.5213% | |
| 61.2227% | |
| 79.1028% | |
| 47.3418% | |
| 32.5389% | |
| -247.0822% | |
| -256.5683% | |
| -250.8176% | |
| -229.8393% | |
| 188.7726% | |
| 215.8679% | |
| 287.8282% | |
| 15,931.1607% | |
| -1,498.0059% | |
| -770.8462% | |
| -1,799.2241% | |
| 101.4275% | |
| 115.0209% | |
| 131.7338% | |
| 89.0402% | |
| -140.4309% | |
| -170.9374% | |
| -163.1718% | |
| -26.7242% | |
| -7.2091% | |
| 8.8658% | |
| 6.6756% | |
| -56.3632% | |
| -66.2636% | |
| -121.8894% | |
| -158.503% |